Clinical trial · Interventional
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CK2 and ATM inhibitors serine/ threonin Kinase combination | Combination Product | — | UNRESOLVED |
| Pazopanib | Drug | Pazopanib | ALIAS |
| Sunitinib | Drug | Sunitinib | ALIAS |
| Temsirolimus | Drug | Temsirolimus | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- CK2(CX4945) and ATM(Ku 60019)
- description
- Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
- interventionNames
- Combination Product: CK2 and ATM inhibitors serine/ threonin Kinase combination
- type
- ACTIVE_COMPARATOR
- label
- Sunitinib
- description
- Treatment of cell culture with Sunitinib
- interventionNames
- Drug: Sunitinib
- type
- ACTIVE_COMPARATOR
- label
- Pazopanib
- description
- Treatment of cell culture with Pazopanib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * major patient treated at the University Hospital of Grenoble for a renal tumor with suspected or confirmed malignancy.This includes non-metastatic patients undergoing renal lumpectomy, partial nephrectomy or total nephrectomy, as well as metastatic or locally advanced cancer patients undergoing cytoreductive surgery who are eligible for medical treatment at the same time Exclusion Criteria: * Contaminated patients with HIV and /or HBV (hepatitis B virus) and / or HCV (hepatitis C virus) positive serology. * Absence or withdrawal of the informed consent of the patient. * Tumors smaller than 2 cm on preoperative imaging
References
Publications (0)
Data not yet available